Eficacia y tolerabilidad de la cinitaprida en pacientes con reflujo gastroesofágico, dispepsia funcional y síndrome de intestino irritable

Background: Prescription for cinitapride includes gastroesophageal reflux, functional dyspepsia and irritable bowel syndrome which have a great medical and social impact. Objective: To evaluate the efficacy and tolerability of cinitapride in the management of these diseases. Material and methods: Clinical and multicentric study that includes 7,320 adult patients (>20 years old), both genders from the outpatient clinic in private practices with diagnosis of gastroesophag eal reflux, functional dyspepsia and irritable bowel syndrome. All patients received cinitapride 1 mg three times a day for four weeks. Results: Global evaluation of symptoms relieve by patient showed considerable improvement in 72.58% of cases, mild improvement in 26.55%, no improvement in 0.84% and worsening of symptoms in 0.03%. On the other hand, the evaluation by physician showed complete relieve of symptoms in 62.35% of cases, mild relieve in 34.27%, minor relieve in 2.92%, no change in 0.42% and worsening of symptoms in 0.05% of cases. Non severe adverse events occurred in 2.9% of patients; headache (n = 27), diarrhea (n = 20), nausea (n = 11), drowsiness (n = 9), dizziness (n = 9), flatulence (n = 9), abdominal pain (n = 9) and meteorism (n = 4) were the most frequent. Diarrhea was presented only in the gastroesophageal reflux (n = 13) and in the dyspepsia (n = 7) groups. Conclusion: Cinitapride is effective and well tolerated in the treatment of adult patients with gastroesophageal reflux, functional